Clinical Trial Update: Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase III study evaluating added exenatide versus placebo to titrated basal insulin glargine in inadequately controlled type 2 diabetes patients; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)
• Insulin Glargine (insulin glargine)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2017-09-18